Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research

Rhea-AI Summary

Waters (NYSE: WAT) unveiled the Xevo MRT P10 Mass Spectrometer, a benchtop high-resolution QToF system for high-throughput multiomics, bioanalysis, and biopharma labs. It delivers up to 20x higher MS/MS sensitivity and 2x faster acquisition than its predecessor, with advanced acquisition modes.

According to Waters, the system supports targeted and untargeted LC‑MS/MS, identifies up to 40% more lipids than a leading alternative, and, with the DESI XS source, enables MS imaging up to 200 Hz with six-fold higher throughput. Global availability is expected in summer 2026.

AI-generated analysis. Not financial advice.

Key Figures

MS/MS sensitivity gain (headline): up to 20x improvement Acquisition speed increase: 2x faster Lipid identification gain: up to 40% more lipids +3 more

6 metrics

MS/MS sensitivity gain (headline) up to 20x improvement MS/MS sensitivity vs prior system

Acquisition speed increase 2x faster Acquisition speeds vs predecessor

Lipid identification gain up to 40% more lipids LC‑MS/MS vs leading alternative benchtop HRMS

MS/MS sensitivity gain (detail) up to 20× higher MS/MS sensitivity vs predecessor

Spatial analysis rate up to 200 Hz Cellular-level spatial analysis with DESI XS source

Throughput improvement six-fold increase Throughput in MS imaging with DESI XS

Market Reality Check

Price: $383.57 Vol: Volume 2,198,982 is 1.79x...

high vol

$383.57 Last Close

Volume Volume 2,198,982 is 1.79x the 20-day average of 1,225,695, signaling elevated interest into this product launch. high

Technical Shares at $383.57 trade 7.38% below the 52-week high of $414.15 and remain above the 200-day MA at $339.95, indicating a firmly established uptrend pre-announcement.

Peers on Argus

WAT was up 4.61% while peers were mixed: ILMN +1.88%, MTD +1.53%, DGX -0.86%, LH...

WAT was up 4.61% while peers were mixed: ILMN +1.88%, MTD +1.53%, DGX -0.86%, LH -0.97%, PKI flat. The lack of uniform direction suggests this move was more company-specific than sector-driven.

Historical Context

5 past events · Latest: May 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 18	Conference appearance	Neutral	+1.2%	Jefferies Global Healthcare Conference fireside chat announced with webcast access.
May 05	Earnings beat	Positive	+13.5%	Q1 2026 revenue and EPS beat guidance with raised full‑year outlook.
Apr 20	Earnings call setup	Neutral	-0.1%	Scheduled Q1 2026 earnings call and webcast details for investors.
Apr 14	Product launch	Positive	+1.9%	Launched omniDAWN MALS detector offering faster runs and extended sizing.
Apr 08	FDA clearance	Positive	+3.6%	FDA cleared Onclarity HPV Self-Collection Kit and approved HPV assay for at-home use.

Pattern Detected

Recent fundamentally positive catalysts (earnings beat, FDA clearance, product launches) have generally coincided with positive share price reactions.

Recent Company History

Over the last few months, Waters has paired strong financial execution with strategic product and regulatory milestones. Q1 2026 results showed revenue of $1.267 billion and raised full‑year guidance, with shares rising 13.54% on that news. FDA clearance of the Onclarity HPV self-collection kit on Apr 8, 2026 and an industry‑first MALS detector launch also saw positive reactions. Today’s high‑performance Xevo MRT P10 MS introduction continues this pattern of innovation supporting multiomics and biopharma workflows.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-03-16

Waters has an effective S-3ASR automatic shelf filed on 2026-03-16, allowing it and certain affiliates to offer an indeterminate amount of equity and debt securities from time to time. The shelf has already been tapped at least once, as indicated by a 424B2 filing on 2026-03-19. Specific offering terms would be detailed in future prospectus supplements.

Market Pulse Summary

This announcement introduces the Xevo MRT P10 MS, a benchtop QToF platform claiming up to 20x higher...

Analysis

This announcement introduces the Xevo MRT P10 MS, a benchtop QToF platform claiming up to 20x higher MS/MS sensitivity, 2x faster acquisition, and up to 40% more lipid identifications than a leading alternative system. It expands Waters’ presence in multiomics, proteomics, and biopharmaceutical analysis, echoing recent product innovations and regulatory wins. Investors may watch adoption in large research centers and how these instruments support the broader post‑acquisition growth strategy.

Key Terms

ms/ms, lc‑ms/ms, high‑resolution mass spectrometer, multiomics, +4 more

8 terms

ms/ms medical

"Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds"

MS/MS, or tandem mass spectrometry, is a laboratory method that identifies and measures molecules by weighing them, breaking them into pieces, and weighing the pieces in a second step to create a unique molecular ‘fingerprint.’ Investors should care because it delivers highly sensitive and specific measurements used in drug development, clinical diagnostics, and quality control; its accuracy can speed trials, support regulatory approval, and drive lab-services revenue.

lc‑ms/ms medical

"Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative"

A laboratory technique that first separates a complex mixture in liquid form and then uses two stages of precise weighing to identify and measure tiny amounts of specific molecules, such as drugs, hormones, or contaminants. Think of it as sorting a mixed bag of candies by type and then weighing each candy to know exactly how many and which ones are present. Investors care because it provides highly reliable data used in drug testing, quality control and regulatory filings, which can affect product approvals, market trust and revenue forecasts.

high‑resolution mass spectrometer technical

"leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research"

A high-resolution mass spectrometer is a laboratory instrument that measures the exact weight of molecules with very high precision, allowing scientists to distinguish substances that are nearly identical—like a high-definition fingerprint scanner for chemicals. For investors, it matters because this capability speeds and de-risks research, quality control, regulatory testing and product development in industries such as pharmaceuticals, biotech, chemicals and environmental testing, often improving time to market and reducing costly errors.

multiomics medical

"next-generation multiomics, therapeutic, and high-throughput workflows."

Multiomics is the combined analysis of different biological data types — such as genes, proteins and small‑molecule chemicals — to build a complete picture of how cells or organisms function. For investors, multiomics matters because it can make drug and diagnostic development more precise and faster by revealing causes, predicting who will benefit from a therapy, and reducing downstream clinical trial surprises — like using multiple camera angles to better understand a complex scene.

lipidomics medical

"advancing lipidomics research and disease understanding."

The systematic study of all fats and fat-like molecules in cells and tissues, including their types, amounts and how they change over time. Think of it as taking a detailed inventory of the body’s oils to see how they signal disease, respond to drugs or indicate treatment effects; for investors, advances in this field can point to new diagnostics, drug targets or precision-medicine tools that may create commercial opportunities or change the value of companies in healthcare and biotech.

quadrupole time-of-flight (qtof) technical

"a high-resolution Quadrupole Time-of-Flight (QToF) System for high-throughput"

A quadrupole time-of-flight (qTOF) is a laboratory instrument that identifies and measures molecules by first filtering them like a gate (the quadrupole) and then timing how fast the pieces travel to a detector (time-of-flight), similar to sorting cars by lane and using speed to tell their weight. Investors care because qTOF systems are key tools in drug discovery, quality control and diagnostics; sales, service contracts and use in validated testing can signal steady revenue and technological competitiveness.

proteomics medical

"growth across multiomics, including proteomics, lipidomics, and metabolomics"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

metabolomics medical

"including proteomics, lipidomics, and metabolomics, as well as biopharmaceutical analysis"

Study of the small molecules and chemical patterns produced by cells, tissues or body fluids, often described as the body’s short-term chemical “fingerprint.” It matters to investors because these fingerprints can reveal how a drug or treatment is working, identify disease markers, guide patient selection, or shorten development time—similar to using a snapshot to judge whether a machine is running efficiently and needs adjustment.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows.

• Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.

• Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response.

MILFORD, Mass., June 1, 2026 /PRNewswire/ -- 74^th ASMS Conference on Mass Spectrometry and Allied Topics—Waters Corporation (NYSE: WAT) today introduced the Waters Xevo™ MRT P10 Mass Spectrometer, a high-resolution Quadrupole Time-of-Flight (QToF) System for high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories. The Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity compared to its predecessor, along with industry-leading speed and expanded acquisition modes to comprehensively support both targeted and untargeted analysis in a single benchtop platform. The system is designed to accelerate biomarker discovery and validation while supporting the identification of disease pathways and therapeutic targets across large-cohort biomedical research and epidemiology studies.

"With the Xevo MRT P10 MS, we are raising the standard for benchtop high-resolution mass spectrometry," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "By combining enhanced MS/MS sensitivity, the industry's fastest benchtop acquisition speeds, and advanced intelligent acquisition modes in LC-MS/MS – and layering in a new benchmark for MS imaging speed and throughput with our DESI XS – this platform empowers researchers to see more biology, accelerate discovery, and make confident decisions. The Xevo MRT P10 MS represents a powerful step forward for our customers working to advance multiomics research and life‑changing therapies."

As researchers pursue deeper analytical insights, they face a bottleneck: generating high quality MS/MS information at the speed required by modern workflows. The Xevo MRT P10 MS is engineered to solve that problem. It offers up to 20× greater MS/MS sensitivity, helping scientists detect low-abundance compounds in complex samples.¹ With acquisition speeds twice as fast as its predecessor, it is the fastest benchtop HRMS system currently available.² The new system supports rapid throughput, alongside exceptional resolution and mass accuracy, delivering the highest data quality and confidence. When combined with the DESI XS ion source, rapid spatial analysis is unlocked down to the cellular level at up to 200 Hz, increasing throughput six-fold while preserving image quality.³

"As a core research facility, we must be prepared to respond to challenging and often unexpected client requests, many of which relate to research into complex diseases," said Corey Broeckling, Ph.D., Director, Bioanalysis and Omics Center, Colorado State University. "We leverage the exceptional MS/MS sensitivity and fast acquisition rates of the Xevo MRT P10 MS for multiomics research. Its excellent resolution enables us to separate signals of similar mass at very high acquisition speeds, delivering deep, high-quality coverage while maintaining sub‑ppm mass accuracy. Combined with new acquisition modes, this provides the versatility and data confidence we need across a wide range of omics applications."

The Xevo MRT P10 MS is perfectly positioned to support long-term growth across multiomics, including proteomics, lipidomics, and metabolomics, as well as biopharmaceutical analysis and drug discovery. The instrument unlocks new workflows in high-throughput, deep proteome discovery by combining greater sensitivity with ultra-fast acquisition rates and advanced acquisition modes, allowing confident detection of low-abundance peptides and comprehensive protein identification with rapid separations at scale. In comparative lipid profiling by LC-MS/MS, the Xevo MRT P10 MS enabled identification of up to 40% more lipids than the most competitive alternative system.⁴ These enhancements support more comprehensive biological interpretation in multiomics‑driven research and ultimately drive deeper levels of disease understanding.

The Xevo MRT P10 MS will be showcased at ASMS 2026 and is expected to be available globally beginning summer 2026. For more information or to request a demo, visit the product page.

Additional Resources:

• Product page

Waters, Xevo, and SONAR are trademarks of Waters Corporation or its affiliates. All other marks are the property of their respective owners.

The P in Xevo MRT P10 denotes Premium, the highest performance tier from Waters and 10 marks the first generation of this platform under Waters' new product naming convention.

About Waters Corporation:

Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about.  

References:

1. Up to 20× improvement in MS/MS sensitivity based on internal Waters testing, comparing Xevo MRT P10 MS to a prior‑generation benchtop Xevo MRT MS under controlled conditions; protocol and sample details on file.
2. Maximum acquisition rates (100 Hz MS; 200 Hz MS/MS) versus commercially available benchtop HRMS platforms as of April 2026, based on internal benchmarking.
3. Up to 2x improvement in imaging speed, comparing to current Waters Xevo MRT MS with DESI XS, and up to 4x imaging speed compared to next-best competitive MS imaging system. When combined with the DESI XS ion source, rapid spatial analysis is unlocked down to the cellular level at up to 200 Hz, increasing throughput six-fold while preserving image quality.
4. Up to 40% more lipid identifications based on comparative lipidomics study using matched sample sets across Xevo MRT P10 MS and a leading benchtop HRMS system; protocol and sample details on file.

Contact:

Molly Gluck  
Head of External Communications
Waters Corporation  
508.498.9732
molly_gluck@waters.com   

View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-introduces-unrivaled-sensitivity-and-speed-to-benchtop-hrms-with-xevo-mrt-p10-ms-accelerating-multiomics-research-302786883.html

SOURCE Waters Corporation

FAQ

What is the Waters Xevo MRT P10 MS and who is it designed for (NYSE: WAT)?

The Xevo MRT P10 MS is a benchtop high-resolution QToF mass spectrometer for multiomics, bioanalysis, and biopharmaceutical labs. According to Waters, it targets high-throughput biomarker discovery, disease pathway research, and therapeutic target identification across large-cohort biomedical and epidemiology studies.

How much sensitivity and speed improvement does the Xevo MRT P10 MS offer over its predecessor?

The Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity and 2x faster acquisition versus its predecessor. According to Waters, this helps detect low-abundance compounds, generate high-quality MS/MS data at modern workflow speeds, and maintain high resolution and sub‑ppm mass accuracy.

How does Waters Xevo MRT P10 MS (WAT) enhance lipidomics and multiomics research?

Xevo MRT P10 MS can identify up to 40% more lipids by LC‑MS/MS than a leading alternative benchtop HRMS. According to Waters, its higher sensitivity, fast acquisition, and advanced modes support deeper lipid profiling, multiomics workflows, and more comprehensive biological interpretation in disease research.

What role does the DESI XS source play with the Xevo MRT P10 MS system?

When paired with Xevo MRT P10 MS, the DESI XS source enables rapid MS imaging down to cellular level at up to 200 Hz. According to Waters, this increases spatial analysis throughput six-fold while preserving image quality, supporting higher-confidence disease and treatment-response studies.

When will the Waters Xevo MRT P10 MS be available globally and how can users request a demo?

Xevo MRT P10 MS is expected to be available globally starting summer 2026. According to Waters, the system will be showcased at ASMS 2026, and interested researchers can request a demo or learn more through the dedicated online product page.

What applications does the Xevo MRT P10 MS support in proteomics and metabolomics research?

Xevo MRT P10 MS supports high-throughput deep proteome discovery and broad metabolomics applications. According to Waters, greater sensitivity, ultra-fast acquisition, and advanced modes enable confident detection of low-abundance peptides, comprehensive protein identification, and scalable, rapid separations across diverse multiomics workflows.